ДИАГНОСТИКА И ЛЕЧЕНИЕ ИНФЕКЦИИ HELICOBACTER PYLORI: ПОЛОЖЕНИЯ КОНСЕНСУСА МААСТРИХТ V (2015 Г.)

В статье отражены основные положения консенсуса Маастрихт V (Флоренция, 2015 г.), посвященные вопросам диагностики и лечения инфекции Helicobacterpylori и ассоциированных с этим патогеном заболеваний гастродуоденальной зоны. Рассмотренные положения согласи- тельного совещания проиллюстрированы как оригинальными, так и собственными комментариями.

1. Маев И.В., Самсонов А.А., Андреев Д.Н. Инфекция Helicobacter pylori. М.: ГЭОТАР-Медиа; 2016, 256 с. Maev I.V., Samsonov A.A., Andreev D.N. Helicobacter pylori infection. M.: GEOTAR-Media; 2016, 256 p. [in Russian]

2. Abadi A.T., Kusters J.G. Management of Helicobacter pylori infections. BMC Gastroenterol. 2016; 16(1): 94.

3. Atkinson N.S., Braden B. Helicobacter Pylori Infection: Diagnostic Strategies in Primary Diagnosis and After Therapy. Dig. Dis. Sci. 2016; 61(1): 19-24.

4. Burucoa C., Delchier J.C., Courillon-Mallet A. et al. Comparative evaluation of 29 commercial Helicobacter pylori serological kits. Helicobacter 2013; 18: 169 –179.

5. Calvet X., García N., López T. et al. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol. Ther. 2000; 14: 603– 609.

6. Calvet X. Diagnosis of Helicobacter pylori Infection in the Proton Pump Inhibitor Era. Gastroenterol Clin. North. Am. 2015; 44(3): 507-518.

7. Chen H.N., Wang Z., Li X. et al. Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia: evidence from a meta-analysis. Gastric Cancer 2016; 19: 166 –175.

8. Chey W.D., Leontiadis G.I., Howden C.W., Moss S.F. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017 Feb; 112(2): 212-239.

9. Dixon M.F., Genta R.M., Yardley J.H. et al. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am.J. Surg. Pathol. 1996; 20: 1161–1181.

10. Ferwana M., Abdulmajeed I., Alhajiahmed A. et al. Accuracy of urea breath test in Helicobacter pylori infection: metaanalysis. World. J. Gastroenterol. 2015; 21: 1305 –1314.

11. Flores H.B., Salvana A., Ang E.L.R. et al. Duration of protonpump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis. Gastroenterology 2010; 138: S-340.

12. Gatta L., Vakil N., Ricci C. et al. Effect of proton pump inhibitors and antacid therapy on 13C urea breath tests and stool test for Helicobacter pylori infection. Am. J. Gastroenterol. 2004; 99: 823– 829.

13. Gisbert J.P., Pajares J.M. Review article: 13C-urea breath test in the diagnosis of Helicobacter pylori infection—a critical review. Aliment. Pharmacol. Ther. 2004; 20: 1001–1017.

14. Gisbert J.P. Helicobacter pylori-related diseases. Gastroenterol. Hepatol. 2016 Sep; 39 Suppl 1: 36-46.

15. Graham D.Y., Lee Y.C., Wu M.S. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicinebased evidence. Clin. Gastroenterol. Hepatol. 2014; 12: 177–186.

16. Hartman D.J., Owens S.R. Are routine ancillary stains required to diagnose Helicobacter infection in gastric biopsy specimens? An institutional quality assurance review. Am J Clin Pathol 2012;137:255 – 60.

17. He L, Deng T, Luo H. Meta-analysis of sequential, concomitant and hybrid therapy for Helicobacter pylori eradication. Intern. Med. 2015; 54: 703–710.

18. Kim J.S., Park S.M., Kim B.W. Sequential or concomitant therapy for eradication of Helicobacter pylori infection: a systematic review and meta-analysis. J. Gastroenterol. Hepatol. 2015; 30: 1338 –1345.

19. Kongchayanun C., Vilaichone R.K., Pornthisarn B. et al. Pilot studies to identify the optimum duration of concomitant Helicobacter pylori eradication therapy in Thailand. Helicobacter 2012; 17: 282–285.

20. Kuipers E.J. In through the out door: serology for atrophic gastritis. Eur. J. Gastroenterol. Hepatol. 2003; 15: 877– 879.

21. Kwon B., Park E., Lee D. et al. Effectiveness of 5-day and 7-day quadruple ‘concomitant’ therapy regimen for Helicobacter pylori infection in Korea. Helicobacter 2011; 16(Suppl 1): 135.

22. Labenz J. Current role of acid suppressants in Helicobacter pylori eradication therapy. Best Pract. Res. Clin. Gastroenterol. 2001; 15: 413– 431.

23. Leodolter A., Domínguez-Muñoz J.E., von Arnim U. et al. Validity of a modified 13C-urea breath test for preand posttreatment diagnosis of Helicobacter pylori infection in the routine clinical setting. Am. J. Gastroenterol. 1999; 94: 2100 –2104.

24. Lim JH, Kim N, Lee HS, et al. Correlation between endoscopic and histological diagnoses of gastric intestinal metaplasia. Gut Liver 2013;7:41–50.

25. Liu W.Z., Xie Y., Cheng H. et al. Fourth Chinese National Consensus Report on the management of Helicobacter pylori infection. J. Dig. Dis. 2013; 14: 211–221.

26. Lu H., Zhang W., Graham D.Y. Bismuth-containing quadruple therapy for Helicobacter pylori: lessons from China. Eur. J. Gastroenterol. Hepatol. 2013; 25: 1134 –1140.

27. Maev I.V., Andreev D.N., Kucheryavyi Yu.A., Dicheva D.T. Host factors influencing the eradication rate of Helicobacter pylori. World Applied. Sci. J. 2014; 30: 134-140.

28. Malfertheiner P., Megraud F., O’Morain C.A. et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017; 66(1): 6-30.

29. Miki K. Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels — “ABC method”. Proc. Jpn. Acad. Ser. B. Phys. Biol. Sci. 2011; 87(7): 405-414.

30. Moon S.W., Kim T.H. et al. United rapid urease test is superior than separate test in detecting Helicobacter pylori at the gastric antrum and body specimens. Clin. Endosc. 2012; 45: 392–396.

31. Morgan D.R., Crowe S.E. Helicobacter pylori infection. In.: Sleisenger and Fordtran’s Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management / edited by Mark Feldman, Lawrence S Friedman, Laurence J Brandt. — 10th ed. 2015: 856-884.

32. Nishizawa T., Maekawa T., Watanabe N. et al. Clarithromycin versus metronidazole as first-line Helicobacter pylori eradication: a multicenter, prospective, randomized controlled study in Japan. J. Clin. Gastroenterol. 2015; 49: 468 – 471.

33. O’Connor A., Fischbach W., Gisbert J.P., O’Morain C. 2016; 21 Suppl 1: 55-61.

34. Price A.B. The Sydney system: histological division. J. Gastroenterol. Hepatol. 1991; 6: 209 –222.

35. Rimbara E., Fischbach L.A., Graham D.Y. Optimal therapy for Helicobacter pylori infections. Nat. Rev. Gastroenterol. Hepatol. 2011; 8: 79 – 88.

36. Rokkas T., Pistiolas D., Sechopoulos P. et al. The long-term impact of Helicobacter pylori eradication on gastric histology: a systematic review and meta-analysis. Helicobacter 2007; 12(Suppl 2): 32–38.

37. Selgrad M., Meissle J., Bornschein J. et al. Antibiotic susceptibility of Helicobacter pylori in central Germany and its relationship with the number of eradication therapies. Eur. J. Gastroenterol. Hepatol. 2013; 25: 1257–1260.

38. Shiota S., Reddy R., Alsarraj A. et al. Antibiotic resistance of Helicobacter pylori among male United States veterans. Clin. Gastroenterol. Hepatol. 2015; 13: 1616 –1624.

39. Sugimoto M., Furuta T. Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype. World J. Gastroenterol. 2014; 20: 6400 – 6411.

40. Tang H.L., Li Y., Hu Y.F. et al. Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials. PLoS One 2013; 8: e62162.

41. Thung I., Aramin H., Vavinskaya V. et al. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment. Pharmacol. Ther. 2016; 43: 514 –533.

42. Treiber G., Wittig J., Ammon S. et al. Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study). Arch. Intern. Med. 2002; 162: 153–160.

43. Vaira D., Vakil N., Menegatti M. et al. The stool antigen test for detection of Helicobacter pylori after eradication therapy. Ann. Intern. Med. 2002; 136: 280 –287.

44. Vallve M., Vergara M., Gisbert J.P. et al. Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis. Aliment. Pharmacol. Ther. 2002; 16: 1149 –1156.

45. Villoria A., Garcia P., Calvet X. et al. Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. Aliment. Pharmacol. Ther. 2008; 28: 868 – 877.

46. Wang B., Wang Y.H., Lv Z.F. et al. Review: efficacy and safety of hybrid therapy for Helicobacter pylori infection: a systematic review and meta-analysis. Helicobacter 2015; 20: 79 – 88.

47. Wang J., Xu L., Shi R. et al. Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: a meta-analysis. Digestion 2011; 83: 253–260.

48. Watabe H., Mitsushima T., Yamaji Y. et al. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut 2005; 54: 764 –768.